Lyudmila Bazhenova

Title(s)Clinical Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Research Interests
    Dr. Bazhenova’s clinical practice and research concentrate on lung cancer, particularly as this relates to females and non-smokers. She actively participates in cooperative group trials, and takes an active role in designing and implementing clinical investigations, including phase II studies and correlative science projects with several UCSD investigators. She believes in a multidisciplinary approach to lung cancer when radiation and surgery plays an important role in patient management. She leads a weekly lung tumor board, so patients can benefit from input of different sub-specialists

    Education and Training
    MD - Nizhny Novgorod State Medical Academy, Nizhny Novgorod, Russia - 1988-1994
    Resident, Chief Resident and Research Fellowship - Clinical Hospital #38,Nizhny Novgorod State Medical Academy Nizhny Novgorod, Russia - 1994-1995
    Intern/Resident - UCLA VA Medical Center - 1999-2002
    Fellowship - Hematology-Oncology, Scripps-Green Hospital, La Jolla, CA - 2002-2005

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2. J Clin Oncol. 2024 Nov 12; JCO2402133. Bazhenova L, Ismaila N, Abu Rous F, Alluri K, Freeman-Daily J, Halmos B, Malhotra N, Marrone KA, Puri S, Qin A, Leighl NB. PMID: 39531596.
      View in: PubMed   Mentions:    Fields:    
    2. Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study. Future Oncol. 2024 Nov 08; 1-15. Bazhenova L, Kim DW, Cho BC, Goel S, Heist R, Werner TL, Eaton KD, Wang JS, Pant S, Adkins DR, Blakely CM, Yan X, Neuteboom S, Christensen JG, Chao R, Bauer T. PMID: 39513224.
      View in: PubMed   Mentions:    Fields:    
    3. Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respir Med. 2024 Oct; 12(10):775-786. Han B, Feinstein T, Shi Y, Chen G, Yao Y, Hu C, Shi J, Feng J, Wu H, Cheng Y, Guo QS, Jie Z, Ye F, Zhang Y, Liu Z, Mao W, Zhang L, Lu J, Zhao J, Bazhenova L, Ruiz J, Kloecker GH, Sujith KR, Oliff IA, Wong M, Liu B, Wu Y, Huang L, Sun Y, DUBLIN-3 study group. PMID: 39265599.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    4. Proceedings of the 1st biannual bridging the gaps in lung cancer conference. Oncologist. 2024 Sep 05. Florez N, Patel SP, Wakelee H, Bazhenova L, Massarelli E, Salgia R, Stiles B, Peters S, Malhotra J, Gadgeel SM, Nieva JJ, Afkhami M, Hirsch FR, Gubens M, Cascone T, Levy B, Sabari J, Husain H, Ma PC, Backhus LM, Iyengar P, Lee P, Miller R, Sands J, Kim E. PMID: 39237103.
      View in: PubMed   Mentions:    Fields:    
    5. Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology. Lung Cancer. 2024 Oct; 196:107935. Marks JA, Gandhi N, Halmos B, Marmarelis ME, Yeon Kim S, Bazhenova L, Ramalingam SS, Xiu J, Walker P, Oberley MJ, Ma PC, Liu SV. PMID: 39241297.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. Lung Cancer. 2024 Sep; 195:107928. Mansfield AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, Patel S, Bazhenova LA, Forde P, Lou Y, Dizona P, Villaruz LC, Arnold SM, Khalil M, Kindler HL, Koczywas M, Pacheco J, Rolfo C, Xia B, Mikula E, Chen L, Patel K, Smith KER, Cao L, Shapiro G, Costello BA, Adjei A, Sharon E, Moscow JA, Zamboni W, Hassan R. PMID: 39197359; PMCID: PMC11416719.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    7. Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial. Clin Cancer Res. 2024 Apr 15; 30(8):1655-1668. Parra ER, Zhang J, Duose DY, Gonzalez-Kozlova E, Redman MW, Chen H, Manyam GC, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli ML, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang HH, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray JE, Herbst RS, Wistuba II, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee JJ, Zhang J, Haymaker C. PMID: 38277235; PMCID: PMC11016892.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    8. Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma. Cancers (Basel). 2024 Mar 22; 16(7). Yun KM, Bazhenova L. PMID: 38610930; PMCID: PMC11011044.
      View in: PubMed   Mentions: 1  
    9. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3. J Clin Oncol. 2024 Apr 10; 42(11):e1-e22. Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, Masters G, Schenk EL, Schneider BJ, Sequist L, Singh N, Bazhenova L, Blanchard E, Freeman-Daily J, Furuya N, Halmos B, Azar IH, Kuruvilla S, Mullane M, Naidoo J, Reuss JE, Spigel DR, Owen DH, Patel JD. PMID: 38417091.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    10. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3. J Clin Oncol. 2024 Apr 10; 42(11):e23-e43. Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, Masters G, Schenk EL, Schneider BJ, Sequist L, Singh N, Bazhenova L, Blanchard E, Freeman-Daily J, Furuya N, Halmos B, Azar IH, Kuruvilla S, Mullane M, Naidoo J, Reuss JE, Spigel DR, Owen DH, Patel JD. PMID: 38417098.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    11. Repotrectinib in a Patient With NTRK Fusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome. JCO Precis Oncol. 2024 Jan; 8:e2300265. Yun KM, Narezkina A, Redfern C, Velasco K, Bazhenova L. PMID: 38271657; PMCID: PMC10830087.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study. Target Oncol. 2023 Jul; 18(4):571-583. Wang M, Slatter S, Sussell J, Lin CW, Ogale S, Datta D, Butte AJ, Bazhenova L, Rudrapatna VA. PMID: 37341856; PMCID: PMC10345061.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. Corrigendum to "Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level": [Annals of Oncology 34 (2023) 327-332]. Ann Oncol. 2023 Aug; 34(8):725-726. Bazhenova L. PMID: 37296057.
      View in: PubMed   Mentions:    Fields:    
    14. Metastatic HER2-amplified non-small-cell lung cancer treated with trastuzumab deruxtecan. BMJ Case Rep. 2023 May 08; 16(5). Yun KM, Bazhenova L. PMID: 37156567; PMCID: PMC10173996.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I. J Natl Cancer Inst. 2023 04 11; 115(4):437-446. Unger JM, Qian L, Redman MW, Tavernier SS, Minasian L, Sigal EV, Papadimitrakopoulou VA, Leblanc M, Cleeland CS, Dzingle SA, Summers TJ, Chao H, Madhusudhana S, Villaruz L, Crawford J, Gray JE, Kelly KL, Gandara DR, Bazhenova L, Herbst RS, Gettinger SN, Moinpour CM. PMID: 36625510; PMCID: PMC10086628.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    16. Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib. Oncologist. 2023 04 06; 28(4):287-296. Zhang J, Johnson M, Barve M, Bazhenova L, McCarthy M, Schwartz R, Horvath-Walsh E, Velastegui K, Qian C, Spira A. PMID: 36892150; PMCID: PMC10078892.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    17. Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG). JCO Clin Cancer Inform. 2023 04; 7:e2200165. Lee SM, Fan W, Wang A, Vaidya R, Redman MW, Gettinger SN, Bazhenova L, Herbst RS, Hershman DL, Unger JM. PMID: 37084329; PMCID: PMC10281446.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    18. Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level. Ann Oncol. 2023 04; 34(4):327-332. Bazhenova L. PMID: 37061249.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. Management of toxicities associated with immune checkpoint inhibitors. Clin Adv Hematol Oncol. 2023 Mar; 21(3):142-149. Yun KM, Bazhenova L. PMID: 36867558.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer. Expert Rev Anticancer Ther. 2023 Jan; 23(1):95-106. Yang JC, Zhou C, Jänne PA, Ramalingam SS, Kim TM, Riely GJ, Spira AI, Piotrowska Z, Mekhail T, Garcia Campelo MR, Felip E, Bazhenova L, Jin S, Kaur M, Diderichsen PM, Gupta N, Bunn V, Lin J, N Churchill E, Mehta M, Nguyen D. PMID: 36537204.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    21. Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors. Target Oncol. 2023 01; 18(1):105-118. Kollmannsberger C, Hurwitz H, Bazhenova L, Cho BC, Hong D, Park K, Reckamp KL, Sharma S, Der-Torossian H, Christensen JG, Faltaos D, Potvin D, Tassell V, Chao R, Shapiro GI. PMID: 36459255.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    22. Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets. Mol Oncol. 2023 02; 17(2):230-237. Viteri S, Minchom A, Bazhenova L, Ou SI, Bauml JM, Shell SA, Schaffer M, Gu J, Rose JB, Curtin JC, Mahadevia P, Girard N. PMID: 36269676; PMCID: PMC9892822.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    23. Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer. Cancer Treat Res Commun. 2022; 33:100637. Bazhenova L, Kish J, Cai B, Caro N, Feinberg B. PMID: 36162323.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    24. Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project. Cancer Treat Res Commun. 2022; 33:100623. Bridgewater J, Jiao X, Parimi M, Flach C, Stratford J, Kamburov A, Schmitz AA, Zong J, Reeves JA, Keating K, Bruno A, Fellous M, Pereira MB, Bazhenova L. PMID: 36041373.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    25. Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment. JCO Precis Oncol. 2022 08; 6:e2100551. Giustini NP, Patel SP, Myall NJ, Fernando do Prado Moura J, Kulkarni A, Chao RC, Wakelee H, Bazhenova L. PMID: 35952324.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    26. Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials. JTO Clin Res Rep. 2022 Sep; 3(9):100385. Gettinger SN, Huber RM, Kim DW, Bazhenova L, Hansen KH, Tiseo M, Langer CJ, Paz-Ares Rodríguez LG, West HL, Reckamp KL, Weiss GJ, Smit EF, Hochmair MJ, Kim SW, Ahn MJ, Kim ES, Groen HJM, Pye J, Liu Y, Zhang P, Vranceanu F, Camidge DR. PMID: 36065449; PMCID: PMC9440305.
      View in: PubMed   Mentions: 8  
    27. Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors. Clin Lung Cancer. 2022 11; 23(7):571-577. Girard N, Minchom A, Ou SI, Gadgeel SM, Trigo J, Viteri S, Bauml JM, Londhe A, Mahadevia P, Bazhenova L. PMID: 36085282.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    28. Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Cancer Discov. 2022 07 06; 12(7):1676-1689. Wang M, Yang JC, Mitchell PL, Fang J, Camidge DR, Nian W, Chiu CH, Zhou J, Zhao Y, Su WC, Yang TY, Zhu VW, Millward M, Fan Y, Huang WT, Cheng Y, Jiang L, Brungs D, Bazhenova L, Lee CK, Gao B, Xu Y, Hsu WH, Zheng L, Jänne PA. PMID: 35404393; PMCID: PMC9262839.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    29. First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. Invest New Drugs. 2022 10; 40(5):990-1000. Bauer T, Cho BC, Heist R, Bazhenova L, Werner T, Goel S, Kim DW, Adkins D, Carvajal RD, Alva A, Eaton K, Wang J, Liu Y, Yan X, Christensen J, Neuteboom S, Chao R, Pant S. PMID: 35767205; PMCID: PMC9395446.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    30. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N Engl J Med. 2022 07 14; 387(2):120-131. Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Anderes K, Der-Torossian H, Kheoh T, Velastegui K, Yan X, Christensen JG, Chao RC, Spira AI. PMID: 35658005.
      View in: PubMed   Mentions: 258     Fields:    Translation:HumansCTClinical Trials
    31. Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors. Clin Cancer Res. 2022 May 13; 28(10):2196. Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Lin JJ, Goto K, Lee J, Bazhenova L, John T, Fakih M, Chawla SP, Dziadziuszko R, Seto T, Heinzmann S, Pitcher B, Chen D, Wilson TR, Rolfo C. PMID: 35553647; PMCID: PMC10361215.
      View in: PubMed   Mentions: 1     Fields:    
    32. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clin Cancer Res. 2022 04 01; 28(7):1302-1312. Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Lin JJ, Goto K, Lee J, Bazhenova L, John T, Fakih M, Chawla SP, Dziadziuszko R, Seto T, Heinzmann S, Pitcher B, Chen D, Wilson TR, Rolfo C. PMID: 35144967; PMCID: PMC9365368.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    33. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Med. 2022 07; 11(14):2790-2800. Solomon B, Callejo A, Bar J, Berchem G, Bazhenova L, Saintigny P, Wunder F, Raynaud J, Girard N, Lee JJ, Sulaiman R, Prouse B, Bresson C, Ventura H, Magidi S, Rubin E, Young B, Onn A, Leyland-Jones B, Schilsky RL, Lazar V, Felip E, Kurzrock R. PMID: 35307972; PMCID: PMC9302335.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    34. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy. Lung Cancer. 2022 06; 168:74-82. Minchom A, Viteri S, Bazhenova L, Gadgeel SM, Ou SI, Trigo J, Bauml JM, Backenroth D, Bhattacharya A, Li T, Mahadevia P, Girard N. PMID: 35597172.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    35. Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy. Transl Lung Cancer Res. 2022 Mar; 11(3):452-461. Yu L, Bazhenova L, Gold K, Tran L, Hilburn V, Vu P, Patel SP. PMID: 35399568; PMCID: PMC8988081.
      View in: PubMed   Mentions: 7  
    36. Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC. Cancer Manag Res. 2022; 14:843-850. Yun KM, Bazhenova LA. PMID: 35250311; PMCID: PMC8890401.
      View in: PubMed   Mentions: 4  
    37. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1). J Clin Oncol. 2022 08 10; 40(23):2530-2538. Ou SI, Jänne PA, Leal TA, Rybkin II, Sabari JK, Barve MA, Bazhenova L, Johnson ML, Velastegui KL, Cilliers C, Christensen JG, Yan X, Chao RC, Papadopoulos KP. PMID: 35167329; PMCID: PMC9362872.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansCTClinical Trials
    38. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer. 2021 12; 162:154-161. Bazhenova L, Minchom A, Viteri S, Bauml JM, Ou SI, Gadgeel SM, Trigo JM, Backenroth D, Li T, Londhe A, Mahadevia P, Girard N. PMID: 34818606.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    39. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 01 20; 386(3):241-251. Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA, DESTINY-Lung01 Trial Investigators. PMID: 34534430; PMCID: PMC9066448.
      View in: PubMed   Mentions: 292     Fields:    Translation:HumansCTClinical Trials
    40. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Sep 01; 7(9):1368-1377. Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, Tavernier SS, Yu H, Unger JM, Minichiello K, Highleyman L, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. PMID: 34264316; PMCID: PMC8283667.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCellsCTClinical Trials
    41. An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer. Expert Opin Pharmacother. 2021 Oct; 22(14):1815-1824. Schokrpur S, Hilburn V, Giustini N, Bazhenova L. PMID: 34225542.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    42. Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2021 09; 159:56-65. Kozono DE, Stinchcombe TE, Salama JK, Bogart J, Petty WJ, Guarino MJ, Bazhenova L, Larner JM, Weiss J, DiPetrillo TA, Feigenberg SJ, Chen X, Sun Z, Nuthalapati S, Rosenwinkel L, Johnson EF, Bach BA, Luo Y, Vokes EE. PMID: 34311345.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    43. A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. 2021 08 15; 27(16):4566-4573. Garon EB, Spira AI, Johnson M, Bazhenova L, Leach J, Cummings AL, Candia A, Coffman RL, Janatpour MJ, Janssen R, Gamelin E, Chow LQM. PMID: 34108179.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    44. Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. Clin Cancer Res. 2021 08 01; 27(15):4160-4167. Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, Loong HH, McCoach CE, Weiss J, Kim YJ, Bazhenova L, Park K, Daga H, Besse B, Gautschi O, Rolfo C, Zhu EY, Kherani JF, Huang X, Kang S, Drilon A. PMID: 34088726; PMCID: PMC8447251.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCTClinical Trials
    45. TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting. Target Oncol. 2021 05; 16(3):389-399. Bazhenova L, Lokker A, Snider J, Castellanos E, Fisher V, Fellous M, Nanda S, Zong J, Keating K, Jiao X. PMID: 33893941; PMCID: PMC8105201.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    46. Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs). Lung Cancer (Auckl). 2021; 12:21-34. Giustini N, Bazhenova L. PMID: 33790679; PMCID: PMC8006757.
      View in: PubMed   Mentions: 10  
    47. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discov. 2021 07; 11(7):1688-1699. Riely GJ, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West HL, Mekhail T, Gentzler RD, Nguyen D, Vincent S, Zhang S, Lin J, Bunn V, Jin S, Li S, Jänne PA. PMID: 33632775; PMCID: PMC8295177.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansCTClinical Trials
    48. Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clin Res Rep. 2021 Feb; 2(2):100114. Yang JC, Reckamp KL, Kim YC, Novello S, Smit EF, Lee JS, Su WC, Akerley WL, Blakely CM, Groen HJM, Bazhenova L, Carcereny Costa E, Chiari R, Hsia TC, Golsorkhi T, Despain D, Shih D, Popat S, Wakelee H. PMID: 34589984; PMCID: PMC8474221.
      View in: PubMed   Mentions: 10  
    49. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020 12; 15(12):1907-1918. Yang JC, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, Berz D, Su WC, Yang N, Wang Z, Fang J, Chen J, Nikolinakos P, Lu Y, Pan H, Maniam A, Bazhenova L, Shirai K, Jahanzeb M, Willis M, Masood N, Chowhan N, Hsia TC, Jian H, Lu S. PMID: 32916310.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    50. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 08 27; 383(9):813-824. Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. PMID: 32846060; PMCID: PMC7506467.
      View in: PubMed   Mentions: 308     Fields:    Translation:HumansCTClinical Trials
    51. Commentary: Epidermal growth factor receptor mutations in resectable lung cancer: What is the prognostic importance? J Thorac Cardiovasc Surg. 2021 09; 162(3):676-677. Bazhenova L, Urbanic J, Onaitis M. PMID: 33581906.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    52. Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Targeted Therapy. Clin Chest Med. 2020 06; 41(2):223-235. Giustini NP, Jeong AR, Buturla J, Bazhenova L. PMID: 32402358.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    53. ROS1-rearranged Non-small Cell Lung Cancer. Thorac Surg Clin. 2020 May; 30(2):147-156. Giustini NP, Bazhenova L. PMID: 32327173.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    54. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 02; 21(2):271-282. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial investigators. PMID: 31838007; PMCID: PMC7461630.
      View in: PubMed   Mentions: 581     Fields:    Translation:Humans
    55. Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019 Oct 01; 5(10):1448-1455. Stinchcombe TE, Jänne PA, Wang X, Bertino EM, Weiss J, Bazhenova L, Gu L, Lau C, Paweletz C, Jaslowski A, Gerstner GJ, Baggstrom MQ, Graziano S, Bearden J, Vokes EE. PMID: 31393548; PMCID: PMC6692685.
      View in: PubMed   Mentions: 47     Fields:    
    56. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clin Cancer Res. 2020 01 15; 26(2):439-449. Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM. PMID: 31548343; PMCID: PMC6980768.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    57. Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. J Transl Med. 2019 08 28; 17(1):294. Shishido SN, Carlsson A, Nieva J, Bethel K, Hicks JB, Bazhenova L, Kuhn P. PMID: 31462312; PMCID: PMC6714097.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    58. Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib. J Thorac Oncol. 2019 09; 14(9):1547-1555. Camidge DR, Pabani A, Miller RM, Rizvi NA, Bazhenova L. PMID: 31108247.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    59. On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. Clin Cancer Res. 2019 06 01; 25(11):3341-3351. Brown BP, Zhang YK, Westover D, Yan Y, Qiao H, Huang V, Du Z, Smith JA, Ross JS, Miller VA, Ali S, Bazhenova L, Schrock AB, Meiler J, Lovly CM. PMID: 30796031; PMCID: PMC6548651.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    60. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2019 03 15; 125(6):892-901. Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G. PMID: 30512189.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCTClinical Trials
    61. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. Cancer Discov. 2019 03; 9(3):384-395. Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ. PMID: 30487236; PMCID: PMC6397691.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    62. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol. 2018; 2018. Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. PMID: 30637364; PMCID: PMC6329466.
      View in: PubMed   Mentions: 139     Fields:    
    63. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. J Clin Oncol. 2018 09 10; 36(26):2693-2701. Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN. PMID: 29768119.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCTClinical Trials
    64. Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment. Oncologist. 2018 10; 23(10):1236-1241. Patel NS, Oury A, Daniels GA, Bazhenova L, Patel SP. PMID: 29769383; PMCID: PMC6263128.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    65. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol. 2018 03 01; 29(3):687-693. Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R, Cantarini M, Johnson M, Mitsudomi T, Jänne PA, Yang JC. PMID: 29293889.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansCTClinical Trials
    66. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). Int J Radiat Oncol Biol Phys. 2018 05 01; 101(1):177-185. Urbanic JJ, Wang X, Bogart JA, Stinchcombe TE, Hodgson L, Schild SE, Bazhenova L, Hahn O, Salgia R, Vokes EE. PMID: 29487024; PMCID: PMC6173195.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    67. New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. Ther Adv Respir Dis. 2018 Jan-Dec; 12:1753466618794133. Villanueva N, Bazhenova L. PMID: 30215300; PMCID: PMC6144513.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimals
    68. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2018 01; 19(1):101-114. Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. PMID: 29169877; PMCID: PMC5847342.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    69. Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors. Clin Cancer Res. 2018 01 01; 24(1):43-51. Subbiah V, Grilley-Olson JE, Combest AJ, Sharma N, Tran RH, Bobe I, Osada A, Takahashi K, Balkissoon J, Camp A, Masada A, Reitsma DJ, Bazhenova LA. PMID: 29030354.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    70. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clin Cancer Res. 2017 Oct 01; 23(19):5729-5736. Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R. PMID: 28972084; PMCID: PMC5678984.
      View in: PubMed   Mentions: 118     Fields:    Translation:Humans
    71. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017 11; 16(11):2598-2608. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 28835386; PMCID: PMC5670009.
      View in: PubMed   Mentions: 1166     Fields:    Translation:HumansAnimalsCells
    72. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. Cancer Res. 2017 10 01; 77(19):5419-5427. Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R. PMID: 28807936; PMCID: PMC5626633.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    73. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clin Cancer Res. 2017 Sep 01; 23(17):5101-5111. Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R. PMID: 28539465; PMCID: PMC5581668.
      View in: PubMed   Mentions: 84     Fields:    Translation:Humans
    74. Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. Cancer Epidemiol Biomarkers Prev. 2017 07; 26(7):1139-1145. Boffa DJ, Graf RP, Salazar MC, Hoag J, Lu D, Krupa R, Louw J, Dugan L, Wang Y, Landers M, Suraneni M, Greene SB, Magaña M, Makani S, Bazhenova L, Dittamore RV, Nieva J. PMID: 28446544; PMCID: PMC5500408.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    75. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. PMID: 27836716.
      View in: PubMed   Mentions: 151     Fields:    Translation:HumansCTClinical Trials
    76. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1643-1652. Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, Han JY, Juan O, Dunphy F, Nishio M, Kang JH, Majem M, Mann H, Cantarini M, Ghiorghiu S, Mitsudomi T. PMID: 27751847.
      View in: PubMed   Mentions: 298     Fields:    Translation:HumansCTClinical Trials
    77. Ovarian stimulation in young adult cancer survivors on targeted cancer therapies. Fertil Steril. 2016 Nov; 106(6):1475-1478. Su HI, Connell MW, Bazhenova LA. PMID: 27565250; PMCID: PMC5159276.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    78. Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. Clin Lung Cancer. 2017 01; 18(1):34-42.e2. Leighl NB, Rizvi NA, de Lima LG, Arpornwirat W, Rudin CM, Chiappori AA, Ahn MJ, Chow LQ, Bazhenova L, Dechaphunkul A, Sunpaweravong P, Eaton K, Chen J, Medley S, Poondru S, Singh M, Steinberg J, Juergens RA, Gadgeel SM. PMID: 27686971; PMCID: PMC5474312.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    79. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw. 2016 07; 14(7):825-36. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M. PMID: 27407123; PMCID: PMC10187059.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    80. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016 03; 14(3):255-64. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. PMID: 26957612; PMCID: PMC10181272.
      View in: PubMed   Mentions: 208     Fields:    Translation:Humans
    81. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther. 2016 04; 15(4):743-52. Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R. PMID: 26873727.
      View in: PubMed   Mentions: 97     Fields:    Translation:Humans
    82. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. PMID: 26418953; PMCID: PMC4741715.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    83. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015 Nov; 51(16):2321-9. Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, van den Heuvel MM, Lal R, Kloecker GH, Eaton KD, Chu Q, Dunlop DJ, Jain M, Garon EB, Davis CS, Carrier E, Moses SC, Shawler DL, Fakhrai H. PMID: 26283035.
      View in: PubMed   Mentions: 122     Fields:    Translation:HumansCTClinical Trials
    84. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer. 2015 Sep; 89(3):357-9. Klempner SJ, Bazhenova LA, Braiteh FS, Nikolinakos PG, Gowen K, Cervantes CM, Chmielecki J, Greenbowe JR, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH. PMID: 26187428.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    85. Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw. 2015 May; 13(5):515-24. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M, National comprehensive cancer network. PMID: 25964637.
      View in: PubMed   Mentions: 194     Fields:    Translation:Humans
    86. Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Oncotarget. 2015 Mar 20; 6(8):6029-39. Tsigelny IF, Wheler JJ, Greenberg JP, Kouznetsova VL, Stewart DJ, Bazhenova L, Kurzrock R. PMID: 25760241; PMCID: PMC4467419.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    87. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. Cell Cycle. 2015; 14(8):1252-9. Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R. PMID: 25695927; PMCID: PMC4614867.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    88. Entropy, complexity, and Markov diagrams for random walk cancer models. Sci Rep. 2014 Dec 19; 4:7558. Newton PK, Mason J, Hurt B, Bethel K, Bazhenova L, Nieva J, Kuhn P. PMID: 25523357; PMCID: PMC4894412.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    89. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw. 2014 Dec; 12(12):1738-61. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. PMID: 25505215.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    90. The thrombotic potential of circulating tumor microemboli: computational modeling of circulating tumor cell-induced coagulation. Am J Physiol Cell Physiol. 2015 Feb 01; 308(3):C229-36. Phillips KG, Lee AM, Tormoen GW, Rigg RA, Kolatkar A, Luttgen M, Bethel K, Bazhenova L, Kuhn P, Newton P, McCarty OJ. PMID: 25411332; PMCID: PMC4312838.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    91. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 01; 20(23):5927-36. Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. PMID: 25231400; PMCID: PMC4252585.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansCTClinical Trials
    92. Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer. J Thorac Oncol. 2014 Aug; 9(8):1111-9. Carlsson A, Nair VS, Luttgen MS, Keu KV, Horng G, Vasanawala M, Kolatkar A, Jamali M, Iagaru AH, Kuschner W, Loo BW, Shrager JB, Bethel K, Hoh CK, Bazhenova L, Nieva J, Kuhn P, Gambhir SS. PMID: 25157764; PMCID: PMC4145608.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    93. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. J Neurooncol. 2014 Sep; 119(2):361-8. Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, Schwab R, Fanta P, Helsten T, Bazhenova L, Parker B, Pingle S, Saria MG, Brown BD, Piccioni DE, Kesari S. PMID: 24942463.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    94. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist. 2014 Jun; 19(6):631-6. Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R. PMID: 24797821; PMCID: PMC4041669.
      View in: PubMed   Mentions: 87     Fields:    Translation:Humans
    95. Adrenal metastases in lung cancer: clinical implications of a mathematical model. J Thorac Oncol. 2014 Apr; 9(4):442-6. Bazhenova L, Newton P, Mason J, Bethel K, Nieva J, Kuhn P. PMID: 24736064; PMCID: PMC3989547.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    96. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation. Ther Adv Respir Dis. 2014 Feb; 8(1):3-12. Haidar YM, Rahn DA, Nath S, Song W, Bazhenova L, Makani S, Fuster MM, Sandhu AP. PMID: 24334338.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    97. Stereotactic body radiation therapy in octogenarians with stage I lung cancer. Clin Lung Cancer. 2014 Mar; 15(2):131-5. Sandhu AP, Lau SK, Rahn D, Nath SK, Kim D, Song WY, Gulaya S, Fuster MM, Bazhenova L, Mundt AJ. PMID: 24157245.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    98. An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer. PLoS One. 2013; 8(7):e67733. Nair VS, Keu KV, Luttgen MS, Kolatkar A, Vasanawala M, Kuschner W, Bethel K, Iagaru AH, Hoh C, Shrager JB, Loo BW, Bazhenova L, Nieva J, Gambhir SS, Kuhn P. PMID: 23861795; PMCID: PMC3702496.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    99. Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer. J Thorac Dis. 2013 Apr; 5(2):E53-7. Randall JM, Bharne AA, Bazhenova LA. PMID: 23585959; PMCID: PMC3621950.
      View in: PubMed   Mentions: 3  
    100. Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model. Cancer Res. 2013 May 01; 73(9):2760-9. Newton PK, Mason J, Bethel K, Bazhenova L, Nieva J, Norton L, Kuhn P. PMID: 23447576; PMCID: PMC3644026.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    101. Clinic-based depression screening in lung cancer patients using the PHQ-2 and PHQ-9 depression questionnaires: a pilot study. Support Care Cancer. 2013 May; 21(5):1503-7. Randall JM, Voth R, Burnett E, Bazhenova L, Bardwell WA. PMID: 23325092.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    102. [The proteins of fast phase of inflammation in prognosis of condition of newborn in case of pregnancy complicated by hydramnion and under the risk of intrauterine infection]. Klin Lab Diagn. 2012 Jun; (6):22-5. Botvin'eva IA, Renge LV, Zorina RM, Bazhenova LG, zorina VN. PMID: 22946221.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    103. A stochastic Markov chain model to describe lung cancer growth and metastasis. PLoS One. 2012; 7(4):e34637. Newton PK, Mason J, Bethel K, Bazhenova LA, Nieva J, Kuhn P. PMID: 22558094; PMCID: PMC3338733.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    104. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol. 2012 Feb; 9(1):016001. Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P. PMID: 22306705; PMCID: PMC3387999.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansCells
    105. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology. Phys Biol. 2012 Feb; 9(1):016005. Wendel M, Bazhenova L, Boshuizen R, Kolatkar A, Honnatti M, Cho EH, Marrinucci D, Sandhu A, Perricone A, Thistlethwaite P, Bethel K, Nieva J, Heuvel Mv, Kuhn P. PMID: 22307026; PMCID: PMC3387995.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCellsCTClinical Trials
    106. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol. 2012 Feb; 9(1):016003. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P. PMID: 22306768; PMCID: PMC3387996.
      View in: PubMed   Mentions: 153     Fields:    Translation:HumansCells
    107. High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. Phys Biol. 2012 Feb; 9(1):016004. Nieva J, Wendel M, Luttgen MS, Marrinucci D, Bazhenova L, Kolatkar A, Santala R, Whittenberger B, Burke J, Torrey M, Bethel K, Kuhn P. PMID: 22306961; PMCID: PMC3388002.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCellsCTClinical Trials
    108. Hypofractionated radiotherapy as definitive treatment of stage I non-small cell lung cancer in older patients. Am J Clin Oncol. 2011 Jun; 34(3):254-8. Ahmad E, Sandhu AP, Fuster MM, Messer K, Pu M, Nobiensky P, Bazhenova L, Seagren S. PMID: 20562588.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    109. Frameless image-guided stereotactic body radiation therapy for lung tumors with 4-dimensional computed tomography or 4-dimensional positron emission tomography/ computed tomography. Clin Lung Cancer. 2011 May; 12(3):180-6. Nath SK, Sandhu AP, Jensen L, Kim D, Bharne A, Nobiensky PD, Lawson JD, Fuster MM, Bazhenova L, Song WY, Mundt AJ. PMID: 21663861.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    110. Locoregional and distant failure following image-guided stereotactic body radiation for early-stage primary lung cancer. Radiother Oncol. 2011 Apr; 99(1):12-7. Nath SK, Sandhu AP, Kim D, Bharne A, Nobiensky PD, Lawson JD, Fuster M, Bazhenova L, Song WY, Mundt AJ. PMID: 21429608.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    111. A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature. J Cancer. 2011 Mar 10; 2:153-64. Demoor PA, Matusov Y, Kelly C, Kolan S, Barnachea L, Bazhenova LA. PMID: 21475720; PMCID: PMC3053538.
      View in: PubMed   Mentions: 3  
    112. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):2044-6. Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ. PMID: 21102269.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    113. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010 Apr 15; 16(8):2450-7. Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. PMID: 20332327.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansCTClinical Trials
    114. Definitive radiation therapy for stage I non-small-cell lung carcinoma: institutional experience with contemporary conformal planning. Clin Lung Cancer. 2009 Nov; 10(6):433-7. Sandhu AP, Messer K, Fuster MM, Ahmad E, Pu M, Bazhenova L, Rose M, Seagren S. PMID: 19900862.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    115. [Various acute phase reactants in different types of proliferative diseases of the uterine appendages]. Klin Lab Diagn. 2009 Oct; (10):16-9. Zorina VN, Kozlov IG, Tret'iakova TV, Promzeleva NV, Bazhenova LG, Zorina RM, Riabicheva TG, Zorin NA. PMID: 20000108.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    116. Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins. Proc Natl Acad Sci U S A. 2009 Jul 07; 106(27):11125-30. Page LJ, Suk JY, Bazhenova L, Fleming SM, Wood M, Jiang Y, Guo LT, Mizisin AP, Kisilevsky R, Shelton GD, Balch WE, Kelly JW. PMID: 19549824; PMCID: PMC2708763.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    117. [The serum levels of inflammatory reactants in women with inflammatory diseases of the uterine appendages, who participate in the in-vitro fertilization]. Klin Lab Diagn. 2008 Feb; (2):15-7. Markina LA, Zorina VN, Shramko SV, Zorina RM, Arkhipova SV, Bazhenova LG. PMID: 18354915.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    118. Terminal respiratory unit type lung adenocarcinoma is associated with distinctive EGFR immunoreactivity and EGFR mutations. Appl Immunohistochem Mol Morphol. 2007 Sep; 15(3):242-7. Peterson MR, Piao Z, Bazhenova LA, Weidner N, Yi ES. PMID: 17721266.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    119. [The level of pregnancy-associated alpha2-glycoprotein and the hormonal background during different options of hormonal replacement therapy in the menopausal syndrome]. Klin Lab Diagn. 2007 Jul; (7):24-7. Zorina VN, Predeina EM, Zorina RM, Levchenko VG, Bazhenova LG, Zorin NA. PMID: 17802803.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    120. Intravascular lymphoma: a role for single-agent rituximab. Leuk Lymphoma. 2006 Feb; 47(2):337-41. Bazhenova L, Higginbottom P, Mason J. PMID: 16321868.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    121. Reactive thrombocytosis associated with a pheochromocytoma. Thromb Haemost. 2005 Aug; 94(2):460-2. Bazhenova L, Du EZ, Bhoyrul S, McCallum J, Saven A. PMID: 16113840.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    122. SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. Br J Haematol. 2005 Jun; 129(6):791-4. Mena-Duran AV, Togo SH, Bazhenova L, Cervera J, Bethel K, Senent ML, Nieva J, Sanz GF, Sanz MA, Saven A, Mustelin T. PMID: 15953006.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    Lyudmila's Networks
    Concepts (371)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (64)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California